{"component": "definition", "props": {"groups": [{"size": 5, "snippet": "means all process development activities undertaken with respect to Products, including without limitation activities related to development and optimization of cell lines, expression systems, reagents, upstream process, downstream process, protein modification, development of the Manufacturing process, process scale-up, process characterization, and process validation for bulk drug substance and final dosage forms of the Products and their related placebos.", "snippet_links": [{"key": "process-development-activities", "type": "clause", "offset": [10, 40]}, {"key": "with-respect-to", "type": "clause", "offset": [52, 67]}, {"key": "including-without-limitation", "type": "clause", "offset": [78, 106]}, {"key": "to-development", "type": "clause", "offset": [126, 140]}, {"key": "cell-lines", "type": "clause", "offset": [161, 171]}, {"key": "upstream-process", "type": "definition", "offset": [203, 219]}, {"key": "downstream-process", "type": "definition", "offset": [221, 239]}, {"key": "development-of-the", "type": "clause", "offset": [263, 281]}, {"key": "manufacturing-process", "type": "definition", "offset": [282, 303]}, {"key": "process-validation", "type": "definition", "offset": [353, 371]}, {"key": "bulk-drug-substance", "type": "definition", "offset": [376, 395]}, {"key": "the-products", "type": "clause", "offset": [422, 434]}], "samples": [{"hash": "dKmUnICANcm", "uri": "/contracts/dKmUnICANcm#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.799451828, "published": true}, {"hash": "98Lw931j8Rs", "uri": "/contracts/98Lw931j8Rs#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.7310066223, "published": true}, {"hash": "fMKNF6r4YEI", "uri": "/contracts/fMKNF6r4YEI#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.591375351, "published": true}], "hash": "d558c36d2458905d6ac3429526d939a4", "id": 1}, {"size": 3, "snippet": "means all process development activities undertaken with respect to the Product, including activities related to [***]. \u201cProcess Development Costs\u201d means all costs invoiced by Third Parties to Coherus and/or its Affiliates for Process Development activities after the Effective Date directly resulting from any Process Development efforts as set forth in the Process Development Plan or otherwise approved by the JSC. Process Development Costs shall include [***], such as [***]. For the avoidance of doubt, the term \u2018Process Development Costs\u2019 shall include [***].", "snippet_links": [{"key": "process-development-activities", "type": "clause", "offset": [10, 40]}, {"key": "with-respect-to", "type": "clause", "offset": [52, 67]}, {"key": "the-product", "type": "definition", "offset": [68, 79]}, {"key": "activities-related-to", "type": "clause", "offset": [91, 112]}, {"key": "process-development-costs", "type": "definition", "offset": [121, 146]}, {"key": "all-costs", "type": "definition", "offset": [154, 163]}, {"key": "by-third-parties", "type": "clause", "offset": [173, 189]}, {"key": "after-the-effective-date", "type": "clause", "offset": [258, 282]}, {"key": "resulting-from", "type": "definition", "offset": [292, 306]}, {"key": "development-efforts", "type": "clause", "offset": [319, 338]}, {"key": "process-development-plan", "type": "definition", "offset": [359, 383]}, {"key": "approved-by", "type": "definition", "offset": [397, 408]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [480, 506]}, {"key": "the-term", "type": "clause", "offset": [508, 516]}], "samples": [{"hash": "5tS8IWCWh6n", "uri": "/contracts/5tS8IWCWh6n#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 26.3552360535, "published": true}, {"hash": "2DI14LAiWuK", "uri": "https://investors.coherus.com/static-files/3f3a9641-8a71-48f3-a8bf-eb258a807f34", "label": "investors.coherus.com", "score": 14.9322309494, "published": false}, {"hash": "204BPC9SRvB", "uri": "https://investors.coherus.com/static-files/7de556e0-47a9-431f-976b-ce2f2a11b4f2", "label": "investors.coherus.com", "score": 7.7214236259, "published": false}], "hash": "77c7a7b1aa9a405d503964753b94fa1c", "id": 2}, {"size": 3, "snippet": "means all process development activities undertaken with respect to the Product, including activities related to [***]. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.", "snippet_links": [{"key": "process-development-activities", "type": "clause", "offset": [10, 40]}, {"key": "with-respect-to", "type": "clause", "offset": [52, 67]}, {"key": "the-product", "type": "definition", "offset": [68, 79]}, {"key": "activities-related-to", "type": "clause", "offset": [91, 112]}, {"key": "certain-information", "type": "clause", "offset": [126, 145]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [172, 244]}, {"key": "confidential-treatment", "type": "definition", "offset": [246, 268]}], "samples": [{"hash": "e8pKTEKs5aX", "uri": "/contracts/e8pKTEKs5aX#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.799451828, "published": true}, {"hash": "dfPZOPbSBwI", "uri": "/contracts/dfPZOPbSBwI#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.7310066223, "published": true}, {"hash": "4k4DtVroMxx", "uri": "/contracts/4k4DtVroMxx#process-development", "label": "License Agreement (Coherus BioSciences, Inc.)", "score": 25.591375351, "published": true}], "hash": "d307cb760ff69fc0a20bb7940be06a1e", "id": 3}, {"size": 2, "snippet": "means the period commencing with a processing run using the Working Seed and ending on Validation;", "snippet_links": [{"key": "the-period", "type": "clause", "offset": [6, 16]}, {"key": "the-working", "type": "clause", "offset": [56, 67]}], "samples": [{"hash": "g99BccA4jQN", "uri": "/contracts/g99BccA4jQN#process-development", "label": "Contract Manufacturing Agreement (Acambis PLC)", "score": 20.0, "published": true}, {"hash": "dArpw1fe6t5", "uri": "/contracts/dArpw1fe6t5#process-development", "label": "Contract Manufacturing Agreement (Acambis PLC)", "score": 19.0, "published": true}], "hash": "b49d518562f7276ed283b83732f53796", "id": 4}, {"size": 2, "snippet": "means, with respect to a product, all process development, process improvements, manufacturing scale-up, qualification and validation and quality assurance/quality control with respect to such product.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "process-improvements", "type": "definition", "offset": [59, 79]}, {"key": "qualification-and-validation", "type": "clause", "offset": [105, 133]}, {"key": "quality-assurance", "type": "definition", "offset": [138, 155]}, {"key": "quality-control", "type": "definition", "offset": [156, 171]}], "samples": [{"hash": "3pcnvNTHA1O", "uri": "/contracts/3pcnvNTHA1O#process-development", "label": "Collaboration and License Agreement (REGENXBIO Inc.)", "score": 36.3593444824, "published": true}, {"hash": "5KPwcCsKflY", "uri": "/contracts/5KPwcCsKflY#process-development", "label": "Collaboration and License Agreement (REGENXBIO Inc.)", "score": 32.8357276917, "published": true}], "hash": "72092097a45eb04ec9006efe25dc8892", "id": 5}, {"size": 2, "snippet": "The method for manufacture, harvesting and purification of the Product comprising of Upstream Process and Downstream Process as described herein; \u201cUpstream Process\u201d shall mean the entire process from early cell isolation and cultivation, to cell banking and culture expansion of the cells until final harvest (termination of the culture and collection of the live cell batch); \u201cDownstream Process\u201d shall mean the bioprocess where the cell mass from the Upstream Process are processed to meet purity and quality requirements. Downstream Processing includes cell disruption, a purification section, a polishing section, analysis of final product, formulation and storage; [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. \u201cCertificate of Analysis\u201d Certificate of analysis form issued by Kemwell and confirming that the Product belonging to each Batch to which the certificate relates, meets the applicable Specifications (including the results of analysis and testing of such Product), cGMP (in the case of cGMP Batches), Applicable Laws and such other criteria as identified on the certificate, in a form agreed to by the Client;", "snippet_links": [{"key": "the-method", "type": "definition", "offset": [0, 10]}, {"key": "the-product", "type": "definition", "offset": [59, 70]}, {"key": "upstream-process", "type": "definition", "offset": [85, 101]}, {"key": "final-harvest", "type": "definition", "offset": [295, 308]}, {"key": "termination-of-the", "type": "clause", "offset": [310, 328]}, {"key": "quality-requirements", "type": "clause", "offset": [503, 523]}, {"key": "downstream-processing", "type": "clause", "offset": [525, 546]}, {"key": "final-product", "type": "definition", "offset": [630, 643]}, {"key": "and-storage", "type": "clause", "offset": [657, 668]}, {"key": "certain-confidential-information", "type": "clause", "offset": [678, 710]}, {"key": "contained-in", "type": "definition", "offset": [711, 723]}, {"key": "the-information", "type": "clause", "offset": [784, 799]}, {"key": "not-material", "type": "clause", "offset": [807, 819]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [829, 881]}, {"key": "certificate-of-analysis", "type": "definition", "offset": [884, 907]}, {"key": "issued-by", "type": "clause", "offset": [938, 947]}, {"key": "the-certificate", "type": "clause", "offset": [1021, 1036]}, {"key": "applicable-specifications", "type": "definition", "offset": [1056, 1081]}, {"key": "in-the-case", "type": "clause", "offset": [1153, 1164]}, {"key": "applicable-laws", "type": "definition", "offset": [1183, 1198]}, {"key": "other-criteria", "type": "clause", "offset": [1208, 1222]}, {"key": "by-the-client", "type": "clause", "offset": [1277, 1290]}], "samples": [{"hash": "dE9xGBJ2mYH", "uri": "/contracts/dE9xGBJ2mYH#process-development", "label": "Master Services Agreement (Shattuck Labs, Inc.)", "score": 36.1724845996, "published": true}, {"hash": "6sgFpa2YlwH", "uri": "/contracts/6sgFpa2YlwH#process-development", "label": "Master Services Agreement (Shattuck Labs, Inc.)", "score": 35.2334022522, "published": true}], "hash": "bb7641532d9e414eeb8daa31c5106d9b", "id": 6}, {"size": 2, "snippet": "shall be deemed to be initiated, with respect to a particular TA Library, at such time as synthetic feasibility studies used to define an efficient synthetic process for production of such TA Library have been commenced.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [33, 48]}, {"key": "feasibility-studies", "type": "clause", "offset": [100, 119]}], "samples": [{"hash": "gpKRiGv9XSg", "uri": "/contracts/gpKRiGv9XSg#process-development", "label": "Compound Library Agreement (Array Biopharma Inc)", "score": 18.0, "published": true}, {"hash": "9kSScpPgCfZ", "uri": "/contracts/9kSScpPgCfZ#process-development", "label": "Compound Library Agreement (Array Biopharma Inc)", "score": 18.0, "published": true}], "hash": "5885e34df6990da32f0c6323fd890b31", "id": 7}, {"size": 2, "snippet": "means the exploration, identification, development and scale-up, pursuant to a Statement of Work, of (i) one or more new or improved Synthetic Pathways for manufacturing OLED Chemicals in quantities sufficient for supply on a commercial scale and on a cost-effective basis, including any processes intended to qualify as Validated Processes; (ii) new or improved Materials Specifications for such OLED Chemicals; and (iii) new or improved analytical methodologies, data and data analyses for characterizing such OLED Chemicals.", "snippet_links": [{"key": "pursuant-to-a", "type": "definition", "offset": [65, 78]}, {"key": "statement-of-work", "type": "definition", "offset": [79, 96]}, {"key": "synthetic-pathways", "type": "clause", "offset": [133, 151]}, {"key": "oled-chemicals", "type": "definition", "offset": [170, 184]}, {"key": "commercial-scale", "type": "definition", "offset": [226, 242]}, {"key": "to-qualify", "type": "clause", "offset": [307, 317]}, {"key": "materials-specifications", "type": "definition", "offset": [363, 387]}, {"key": "data-analyses", "type": "clause", "offset": [474, 487]}], "samples": [{"hash": "4qFjMrKmgQH", "uri": "/contracts/4qFjMrKmgQH#process-development", "label": "Oled Materials Supply and Service Agreement (Universal Display Corp \\Pa\\)", "score": 18.0, "published": true}], "hash": "8bb6038a945b017abed653f15031a04e", "id": 8}, {"size": 2, "snippet": "means the conduct by Paragon of activities to develop, confirm and/or refine processes for producing the Product and/or activities to develop and/or scale-up a Manufacturing Process suitable for cGMP manufacture of the Product.", "snippet_links": [{"key": "by-paragon", "type": "clause", "offset": [18, 28]}, {"key": "of-activities", "type": "clause", "offset": [29, 42]}, {"key": "to-develop", "type": "definition", "offset": [43, 53]}, {"key": "manufacturing-process", "type": "definition", "offset": [160, 181]}, {"key": "manufacture-of-the-product", "type": "clause", "offset": [200, 226]}], "samples": [{"hash": "8BLLwx1TF2L", "uri": "/contracts/8BLLwx1TF2L#process-development", "label": "Asset Purchase Agreement (Novavax Inc)", "score": 30.5961666107, "published": true}], "hash": "0c75620ad4dee4c99d7d8d2ec88bf11e", "id": 9}, {"size": 1, "snippet": "means the development, qualification, validation and scale-up of the process to manufacture the Product, and any analytic development and Product characterization with respect thereto, beginning with final clone selection and upstream process development and terminating upon the completion of the process scale up activities prior to tech transfer to a CMO, in each case, as described in the CMC Plan, as such CMC Plan exists on upon the Effective Date.", "snippet_links": [{"key": "the-development", "type": "clause", "offset": [6, 21]}, {"key": "the-process", "type": "clause", "offset": [65, 76]}, {"key": "to-manufacture", "type": "definition", "offset": [77, 91]}, {"key": "the-product", "type": "definition", "offset": [92, 103]}, {"key": "beginning-with", "type": "clause", "offset": [185, 199]}, {"key": "upstream-process", "type": "definition", "offset": [226, 242]}, {"key": "completion-of-the", "type": "clause", "offset": [280, 297]}, {"key": "scale-up", "type": "clause", "offset": [306, 314]}, {"key": "prior-to", "type": "definition", "offset": [326, 334]}, {"key": "transfer-to", "type": "definition", "offset": [340, 351]}, {"key": "each-case", "type": "definition", "offset": [362, 371]}, {"key": "cmc-plan", "type": "definition", "offset": [393, 401]}, {"key": "upon-the-effective-date", "type": "clause", "offset": [430, 453]}], "samples": [{"hash": "kuwzJ7S9VO7", "uri": "/contracts/kuwzJ7S9VO7#process-development", "label": "Collaboration and Option Agreement (Aptevo Therapeutics Inc.)", "score": 28.8658447266, "published": true}], "hash": "03ca05d166c1c36298d9474fba820233", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIccHJvY2Vzcy1kZXZlbG9wbWVudCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 30, "snippet": "means all process development activities undertaken with respect to Products, including without limitation activities related to development and optimization of cell lines, expression systems, reagents, upstream process, downstream process, protein modification, development of the Manufacturing process, process scale-up, process characterization, and process validation for bulk drug substance and final dosage forms of the Products and their related placebos.", "title": "Process Development", "id": "process-development", "examples": ["The Client acknowledges that the activities as outlined in the SOW or this Agreement to be undertaken by Kemwell of the <strong>Process Development</strong> phase is experimental in nature and that no favourable or useful result can be assured by \u2587\u2587\u2587\u2587\u2587\u2587\u2587.", "Kemwell shall own any: (a) mechanical and technical trouble-shooting knowhow generally arising in the provision of the Services and carried out solely by Kemwell on non-Client Material, not being in the nature of Improvements to the <strong>Process Development</strong>, or (b) Improvements to Kemwell\u2019s Pre-Existing IPR arising out of the provision of Services (for avoidance of doubt, this shall not include any Improvements made to <strong>Process Development</strong>) (each, a \u201cKemwell Invention\u201d)."], "related": [["research-and-development", "Research and development", "Research and development"], ["clinical-development", "Clinical Development", "Clinical Development"], ["commercial-development", "Commercial Development", "Commercial Development"], ["infill-development", "Infill development", "Infill development"], ["experimental-development", "experimental development", "experimental development"]], "related_snippets": [], "updated": "2026-03-07T04:27:53+00:00"}, "json": true, "cursor": ""}}